Capital International Investors Grows Stock Holdings in Amgen Inc. $AMGN

Capital International Investors increased its position in Amgen Inc. (NASDAQ:AMGN) by 1.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,192,995 shares of the medical research company’s stock after purchasing an additional 282,219 shares during the period. Amgen makes up approximately 0.9% of Capital International Investors’ holdings, making the stock its 26th biggest position. Capital International Investors owned 3.56% of Amgen worth $5,414,296,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock valued at $15,204,047,000 after purchasing an additional 165,281 shares during the period. State Street Corp lifted its position in Amgen by 0.6% during the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after purchasing an additional 177,035 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Amgen by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock valued at $3,619,489,000 after acquiring an additional 291,271 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after purchasing an additional 687,735 shares during the period. Finally, Laurel Wealth Advisors LLC boosted its holdings in Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after buying an additional 6,676,575 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 2.0%

NASDAQ:AMGN opened at $376.97 on Tuesday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The firm has a market capitalization of $203.21 billion, a P/E ratio of 26.49, a PEG ratio of 3.67 and a beta of 0.45. The company’s fifty day moving average price is $354.21 and its 200-day moving average price is $323.38. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Analyst Ratings Changes

A number of analysts have issued reports on AMGN shares. Rothschild & Co Redburn lifted their price target on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Wells Fargo & Company boosted their price objective on shares of Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Piper Sandler boosted their price objective on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, Guggenheim increased their price target on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $354.17.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.